Diagnostic Imaging Can Rule Out CAD in Low-Risk Patients
The study was carried out by a research team from Medical Center Alkmaar (Alkmaar, The Netherlands) led by Friso van der Zant, MD, PhD. The team reviewed and analysed results of CCTA — a well-established, sensitive method of visualising non-obstructive CAD — and calcium scoring to determine the presence of non-calcified plaques in the coronary arteries, amongst women over an 18-month period.
Based on the results, the researchers concluded that the ability to exclude a diagnosis of CAD in about half of patients, while exposing them to only a modest dose of radiation, can have a substantial impact on patient management.
"In the present study, CCTA excluded CAD in 51 percent of the studied cohort and led to changes in patient management in 53 percent," Dr. van der Zant and co-authors write in the journal report. The effective dose from CCTA combined with calcium scoring was substantially lower than 10 mSv in the current study.
The lifetime risk of developing fatal cancer from radiation received from medical imaging examinations with an effective dose of 10 mSv, the researchers note, is estimated to be 1 in 2000, which is >10-fold lower than the lifetime risk of dying in a motor vehicle accident (1 in 108 in the U.S.) and also lower than dying in a pedestrian accident (1 in 749).
Susan G. Kornstein, MD, Editor-in-Chief of Journal of Women's Health, Executive Director of the Virginia Commonwealth University Institute for Women's Health, Richmond, VA, and President of the Academy of Women's Health, comments on Dr. van der Zant's findings: "This study suggests that CCTA combined with calcium scoring is a useful diagnostic tool for excluding coronary artery disease in women with atypical chest pain, with minimal concerns about radiation exposure."
Source: Journal of Women's Health
Image credit: Wikimedia Commons
Published on : Mon, 17 Aug 2015
The enlightened choice for high-field MRI ECHELON Smart is Hitachi’s smart MRI concept which combines ‘SmartQUALITY’ for superb clinical images and sophisticated applications, ‘SmartSPEED’ for reduced examination time, ‘SmartCOMFORT’ for an extraordinary...
Based on Mindray's new generation ultrasound platform, mQuadro, M9 has raised the industry standards to an all new level. Advanced signal transmission and reception processors provide highly sensitive and accurate echo detection. Innovative transducer...
The iViz is a lightweight Point Of Care (POC) ultrasound solution, specifically designed for emerging sub-segments where there is need for a highly accessible and mobile solution that is capable throughout key areas of the patient care path. The iViz...
The Next Evolution in Ultrasound, designed for high expectations ARIETTA 850 ultrasound platform responds to high expectations to answer the ever increasing demands of medical professionals. ARIETTA 850’s fundamental performance has been refined...